Cargando…

2112. Voriconazole for Primary Prophylaxis: A Decade of Trends and Outcomes

BACKGROUND: Invasive fungal infections (IFI) continue to affect the immunocompromised patient population. Many of these patients require antifungal prophylaxis. Voriconazole is an azole antifungal that has been utilized for preventing IFIs but does not have an approved indication for prophylaxis. ME...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mourad, Ahmad, Johnson, Melissa D, Perfect, John R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809050/ http://dx.doi.org/10.1093/ofid/ofz360.1792

Ejemplares similares

2112. Incidence and outcomes of infections in liver transplant recipients during the first year post-transplant.
por: Alpizar-Rivas, Rodolfo M, et al.
Publicado: (2022)

1129. Targeted Voriconazole Prophylaxis in Heart Transplantation Recipients
por: Lin, Michael, et al.
Publicado: (2018)

2112. Assessing the Accuracy of Catheter-Associated Urinary Tract Infections (CAUTI) Identification Using Urinalysis Results
por: Pender, Sarah, et al.
Publicado: (2018)

Primary or Secondary Prophylaxis with Voriconazole Compared with Posaconazole for Prevention of Invasive Fungal Infections After Hematopoietic Stem Cell Transplantation
por: Jansen, Jeffrey W, et al.
Publicado: (2017)

1291. Safety of Isavuconazole Compared with Voriconazole as Primary Antifungal Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients
por: Bogler, Yael, et al.
Publicado: (2020)

2105. Liposomal Amphotericin B Use Before and After Implementation of Voriconazole Prophylaxis in Cancer Patients
por: Shams, Madeeha, et al.
Publicado: (2019)

1733. Voriconazole Prophylaxis Following Allogeneic Hematopoietic Stem Cell Transplant: How Much Is Enough, Are Low Voriconazole Levels Associated With Opportunistic Infections, and What Are the Reasons for Discontinuation?
por: Hadjivassiliou, Giorgos, et al.
Publicado: (2019)

Cheiloscopy in gender determination: A study on 2112 individuals
por: Thermadam, Tim Peter, et al.
Publicado: (2020)

QTc Prolongation in Patients Receiving Triazoles and Amiodarone
por: Cook, Katherine, et al.
Publicado: (2017)

Real-World Experience of Voriconazole Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients: A Single-Center Study
por: Chan, Shuk-Ying, et al.
Publicado: (2017)

2112. In vitro Activity of Cefiderocol and Comparator Agents Against Enterobacterales From United States Hospitals Stratified by Infection Type (2020-2022)
por: Bryowsky, Jason J, et al.
Publicado: (2023)

755. Posaconazole versus voriconazole as antifungal prophylaxis for invasive fungal diseases in patients with hematological malignancies
por: Almutairy, Reem F, et al.
Publicado: (2020)

742. Breakthrough Invasive Fungal Infections with Isavuconazonium Sulfate versus Voriconazole as Primary Antifungal Prophylaxis in Patients with Acute Myeloid Leukemia (AML) who Received Induction Chemotherapy
por: Singam, Hareesh v, et al.
Publicado: (2020)

Comparative study of posaconazole and voriconazole for primary antifungal prophylaxis in patients with pediatric acute leukemia
por: Tu, Songji, et al.
Publicado: (2023)

Paecilomyces Pneumonia Despite Voriconazole Prophylaxis: A Case Report and Literature Review
por: Asif, Abuzar A, et al.
Publicado: (2021)

89. Efficacy and Tolerability of Voriconazole (VOR) vs. Isavuconazole (ISA) Prophylaxis (px) in Preventing Invasive Fungal Infections (IFI) in Lung Transplant Recipients (LTR)
por: Samanta, Palash, et al.
Publicado: (2019)

1639. Efficacy of Voriconazole Prophylaxis Followed by Therapeutic Liposomal Amphotericin B for the Treatment of Murine Pulmonary Aspergillosis Caused by Azole-Resistant Aspergillus fumigatus Strains
por: Olson, Jon, et al.
Publicado: (2018)

1301. Breakthrough Invasive Fungal Infections based on CYP2C19 Levels in Patients Who were on Voriconazole as Primary Antifungal Prophylaxis in Acute Myeloid Leukemia (AML) undergoing Induction Chemotherapy
por: Singam, Hareesh v, et al.
Publicado: (2020)

Voriconazole or Amphotericin B as Primary Therapy Yields Distinct Early Serum Galactomannan Trends Related to Outcomes in Invasive Aspergillosis
por: Chai, Louis Yi Ann, et al.
Publicado: (2014)

Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin - review of the literature
por: Karthaus, M
Publicado: (2011)

Comparative study of prophylaxis with high and low doses of voriconazole in children with malignancy
por: L. Kandaurava, Sviatlana, et al.
Publicado: (2020)

1779. Trends in Anaplasmosis Over the Past Decade: A Review of Clinical Features, Laboratory Data and Outcomes
por: Katragadda, Silpita, et al.
Publicado: (2023)

Suppression of Esophageal Cancer Stem-like Cells by SNX-2112 Is Enhanced by STAT3 Silencing
por: Xu, Dan-dan, et al.
Publicado: (2020)

Voriconazole and target-site penetration into human tissue
por: Weiler, Stefan, et al.
Publicado: (2008)

1176. Antibiotic Prophylaxis Strategies Prior to Left Ventricular Assist Device Implantation: A Survey of Practice
por: Mourad, Ahmad, et al.
Publicado: (2019)

2108. Comparison of Voriconazole vs. Itraconazole in the Treatment of Histoplasmosis – A Retrospective Analysis
por: Hendrix, Michael J, et al.
Publicado: (2019)

Voriconazole as a secondary prophylaxis for cryptococcal meningitis during hematopoietic stem cell transplantation
por: Kashima, Emiko, et al.
Publicado: (2021)

The war on cryptococcosis: A Review of the antifungal arsenal
por: Mourad, Ahmad, et al.
Publicado: (2018)

Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation
por: Marks, David I, et al.
Publicado: (2011)

Clinical effectiveness of posaconazole versus fluconazole as antifungal prophylaxis in hematology–oncology patients: a retrospective cohort study
por: Kung, Hsiang-Chi, et al.
Publicado: (2014)

Present and Future Therapy of Cryptococcus Infections
por: Mourad, Ahmad, et al.
Publicado: (2018)

Proteomic Analysis Reveals Enzymes for β-D-Glucan Formation and Degradation in Levilactobacillus brevis TMW 1.2112
por: Bockwoldt, Julia A., et al.
Publicado: (2022)

1537. Multicenter Study with Therapeutic Drug Monitoring (TDM) of Voriconazole (VRCZ) in Japanese Patients
por: Ueda, Takashi, et al.
Publicado: (2019)

277. Assessment of a Pharmacist-Driven Voriconazole Clinical Practice Guideline in a Children’s Hospital
por: Huppler, Anna, et al.
Publicado: (2018)

A Four-Year Monocentric Study of the Complications of Third Molars Extractions under General Anesthesia: About 2112 Patients
por: Guerrouani, A., et al.
Publicado: (2013)

Histoplasma capsulatum Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient Receiving Voriconazole Prophylaxis
por: Agrawal, Vaibhav, et al.
Publicado: (2020)

The Use of Voriconazole as Primary Prophylaxis for Invasive Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation: A Single Center’s Experience
por: Atoui, Ali, et al.
Publicado: (2021)

Effect of new polyherbal formulations DF1911, DF2112 and DF2813 on CFA induced inflammation in rat model
por: Nagarkar, Bhagyashri, et al.
Publicado: (2017)

Antitumorigenic Effect of Hsp90 Inhibitor SNX-2112 on Tongue Squamous Cell Carcinoma is Enhanced by Low-Intensity Ultrasound
por: Nan, Chuanchuan, et al.
Publicado: (2020)

Characterisation of recombinant GH 3 β-glucosidase from β-glucan producing Levilactobacillus brevis TMW 1.2112
por: Bockwoldt, Julia A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_udvnnaekb2ptj6a875u5q9drj2